Ocriplasmin

Phase 3

Alcon Research (ALC)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Symptomatic Vitreomacular Adhesion

View Full Landscape

Drug Information

Target Indication

Symptomatic Vitreomacular Adhesion

Clinical Trial

NCT01889251

Last updated: 12/25/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA3/13/2013

Jetrea

Jetrea is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ALC

Alcon Research

Ophthalmic Goods•Europe•NASDAQ

Related Pipeline

Ofloxacin otic solutionPhase 3

Acute Otitis Media

Difluprednate 0.05% ophthalmic emulsionPhase 3

Endogenous Anterior Uveitis

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%Phase 3

Allergic Conjunctivitis

AL-4943A ophthalmic solutionPhase 3

Allergic Conjunctivitis

Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solutionPhase 3

Glaucoma, Open-angle

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts